Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame
A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.
You may also be interested in...
The company’s Phase II POC trial did not meet the pain primary endpoint, but fatigue may be more relevant in long COVID despite the condition’s overlap with fibromyalgia.
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.